VSX2 and retinoblastoma: This formulation has been validated in combination with systemic topotecan in two mouse models of retinoblastoma: MDMX mice (constitutively expressing MDMX, Chx10-Cre; Rblox/lox; p107-/-; MDMXTg background) and p53TKO mice (Chx10-Cre; Rblox/lox; p107-/-; p53lox/lox background).